Cholesterol Modulates Amyloid Beta-peptide’s Membrane Interactions

 

 Buy Article Permissions and Reprints

Abstract

The causal relationship between amyloid beta-peptide (Aβ) deposition and Alzheimer’s disease (AD)-specific neuropathological lesions such as neurodegeneration and cortical atrophy is still not known. Mounting evidence points to alterations in cholesterol homeostasis occurring in AD brain that are probably linked to cerebral Aβ pathology. Interestingly, cholesterol not only modulates Aβ synthesis, but also controls interactions between Aβ and neuronal membranes that are regarded as decisive in the initiation of a neurotoxic cascade. This review focuses on the impact of cholesterol on membrane disordering effects of Aβ. Cholesterol is known to be an essential modulator of physicochemical state and functional activity in physiological membranes, and thus plays an essential role in the regulation of synaptic function and cell plasticity. In vitro and in vivo modulation of membrane cholesterol levels affect different cholesterol pools within the plasma membrane bilayer that are differentially sensitive to Aβ’s disrupting effects. Membrane acyl-chains in the hydrocarbon core are most susceptible to Aβ. In this membrane region, cholesterol attenuates the membrane disordering effects of Aβ. This cholesterol pool is modulated by methyl-beta-cyclodextrin (MβCD) treatment in vitro. On the other hand, statin treatment in vivo depletes a cholesterol pool in a membrane area, which is much less susceptible to Aβ’s membrane-disrupting effects. Our findings clearly implicate an involvement of cholesterol in brain membrane alterations occurring during AD. Disease-related changes in membrane cholesterol metabolism may be subtle and restricted to defined membrane pools since total membrane cholesterol levels are mainly unchanged in AD brain. Thus, elucidation of the structure and function of different cholesterol pools is necessary in understanding the coherence between cholesterol and AD.

Abbreviations

Aβ:amyloid beta-peptide

ADAlzheimer’s disease;

ApoEapolipoprotein E

APPamyloid beta-peptide precursor protein

BBBblood brain barrier

CHOD-PAP-cholesteroloxidase-peroxidase-aminophenazonmethodphenol method

CNScentral nervous system

DPHdiphenylhexatriene

HMG-CoAhydroxymethylglutaryl-coenzyme A

MβCDmethyl-beta-cyclodextrin

PMplasma membrane

SPMsynaptosomal plasma membrane

SUVsmall unilammelar vesicle

TNBStrinitrobenzensulfonic acid

TMA-DPHtrimethylammonium-diphenylhexatriene

References

• 1 Abe K, Saito H. Cholesterol does not affect the toxicity of amyloid beta fragment but mimics its effect on MTT formazan exocytosis in cultured rat hippocampal neurons.  Neurosci Res. 1999;  35 165-174
  CrossrefPubMedGoogle Scholar
• 2 Arispe N, Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease Aβ (1 - 40) and (1 - 42) peptides.  FASEB J. 2002;  16 1526-1536
  CrossrefPubMedGoogle Scholar
• 3 Bastiaanse E ML, Hoeld K M, Van der Laarse A. The effect of membrane cholesterol content on ion transport processes in plasma membranes.  Cardiovasc Res. 1997;  33 272-283
  CrossrefPubMedGoogle Scholar
• 4 Bodovitz S, Klein W L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein.  J Biol Chem. 1996;  271 4436-4440
  CrossrefPubMedGoogle Scholar
• 5 Brown D A, London E. Functions of lipid rafts in biological membranes.  Annu Rev Cell Dev Biol. 1998;  14 111-136
  CrossrefPubMedGoogle Scholar
• 6 Eckert G P, Cairns N J, Maras A, Gattaz W F, Müller W E. Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease.  Dement Geriatr Cogn Disord. 2000;  11 181-186
  CrossrefPubMedGoogle Scholar
• 7 Eckert G P, Igbavboa U, Müller W E, Wood W G. Lipid rafts of purified mouse brain synaptosomes prepared with or without detergent reveal different lipid and protein domains.  Brain Res. 2003;  962 144-150
  CrossrefPubMedGoogle Scholar
• 8 Eckert G P, Kirsch C, Mueller W E. Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice.  Neuroreport. 2001;  12 883-887
  PubMedGoogle Scholar
• 9 Eckert G P, Kirsch C, Müller W E. Brain-Membrane Cholesterol in Alzheimer's Disease.  J Nutr Health Aging. 2003;  7 18-23
  PubMedGoogle Scholar
• 10 Eckert G P, Wood W G, Müller W E. Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes.  J Neural Transm. 2001;  108 1051-1064
  CrossrefPubMedGoogle Scholar
• 11 Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.  Proc Natl Acad Sci U.S.A. 2001;  98 5856-5861
  CrossrefPubMedGoogle Scholar
• 12 Gimpl G, Burger K, Fahrenholz F. Cholesterol as modulator of receptor function.  Biochemistry. 1997;  36 10 959-10 974
  PubMedGoogle Scholar
• 13 Hartmann H, Eckert A, Müller W E. Apolipoprotein E and cholesterol affect neuronal calcium signalling: The possible relationship to beta-amyloid neurotoxicity.  Biochem Biophys Res Commun. 1994;  200 1185-1192
  CrossrefPubMedGoogle Scholar
• 14 Howland D S, Trusko S P, Savage M J, Reaume A G, Lang D M, Hirsch J D, Maeda N, Siman R, Greenberg B D, Scott R W, Flood D G. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol.  J Biol Chem. 1998;  273 16 576-16 582
  PubMedGoogle Scholar
• 15 Igbavboa U, Avdulov N A, Chochina S V, Wood W G. Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low-density lipoprotein receptor, apolipoprotein E, or both proteins.  J Neurochem. 1997;  69 1661-1667
  PubMedGoogle Scholar
• 16 Igbavboa U, Avdulov N A, Schroeder F, Wood W G. Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membrane of mice.  J Neurochem. 1996;  66 1717-1725
  PubMedGoogle Scholar
• 17 Ikonen E. Roles of lipid rafts in membrane transport.  Curr Opin Cell Biol. 2001;  13 470-477
  CrossrefPubMedGoogle Scholar
• 18 Jick H, Zornberg G L, Jick S S, Seshadri S, Drachman D A. Statins and the risk of dementia.  Lancet. 2000;  356 1627-1631
  CrossrefPubMedGoogle Scholar
• 19 Kaiser R D, London E. Location of diphenylhexatriene (DPH) and its derivatives within membranes: comparison of different fluorescence quenching analyses of membrane depth.  Biochemistry. 1998;  37 8180-8190
  CrossrefPubMedGoogle Scholar
• 20 Kanfer J N, Sorrentino G, Sitar D S. Amyloid beta peptide membrane perturbation is the basis for its biological effects.  Neurochem Res. 1999;  24 1621-1630
  CrossrefPubMedGoogle Scholar
• 21 Kawahara M, Kuroda Y. Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis.  Brain Res Bull. 2000;  53 389-397
  CrossrefPubMedGoogle Scholar
• 22 Kirsch C, Eckert G P, Koudinov A, Müller W E. Brain Cholesterol, Statins and Alzheimer's Disease. Pharmacopsychiatry (Suppl) 2003; in press
  Google Scholar
• 23 Kirsch C, Eckert G P, Müller W E. Cholesterol attenuates the membrane perturbing properties of β-amyloid peptides.  Amyloid. 2002;  9 149-159
  PubMedGoogle Scholar
• 24 Kirsch C, Eckert G P, Müller W E. Statins affect cholesterol micro-domains in brain plasma membranes.  Biochem Pharmacol. 2003;  65 843-856
  CrossrefPubMedGoogle Scholar
• 25 Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10.  Proc Natl Acad Sci USA. 2001;  98 5815-5820
  CrossrefPubMedGoogle Scholar
• 26 Koudinov A R, Koudinova N V. Essential role for cholesterol in synaptic plasticity and neuronal degeneration.  FASEB J. 2001;  15 1858-1860
  PubMedGoogle Scholar
• 27 Liscum L, Munn N J. Intracellular cholesterol transport.  Biochim Biophys Acta. 1999;  1438 19-37
  PubMedGoogle Scholar
• 28 Mason R P, Shoemaker W J, Shajenko L, Chambers T E, Herbette L G. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol.  Neurobiol Aging. 1992;  13 413-419
  CrossrefPubMedGoogle Scholar
• 29 Mason R P, Shoemaker W J, Shajenko L, Herbette L G. X-ray diffraction analysis of brain lipid membrane structure in Alzheimer's disease and beta-amyloid peptide interactions.  Ann N Y Acad Sci. 1993;  695 54-58
  PubMedGoogle Scholar
• 30 Mecocci P, Cherubini A, Beal M F, Cecchetti R, Chionne F, Polidori M C, Romano G, Senin U. Altered mitochondrial membrane fluidity in AD brain.  Neurosci Lett. 1996;  207 129-132
  CrossrefPubMedGoogle Scholar
• 31 Müller WE; Eckert GP; Scheuer K; Cairns NJ; Maras A; Gattaz W F. Effects of beta-amyloid peptides on the fluidity of membranes from frontal and parietal lobes of human brain. High potencies of A beta 1 - 42 and A beta 1 - 43.  Amyloid. 1998;  5 10-15
  PubMedGoogle Scholar
• 32 Müller W E, Kirsch C, Eckert G P. Membrane-disordering effects of beta-amyloid peptides.  Biochem Soc Trans. 2001;  29 617-623
  CrossrefPubMedGoogle Scholar
• 33 Müller W E, Koch S, Eckert A, Hartmann H, Scheuer K. Beta-Amyloid peptide decreases membrane fluidity.  Brain Res. 1995;  674 133-136
  CrossrefPubMedGoogle Scholar
• 34 Puglielli L, Konopka G, Pack-Chung E, Ingano L A, Berezovska O, Hyman B T, Chang T Y, Tanzi R E, Kovacs D M. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide.  Nat Cell Biol. 2001;  3 905-912
  CrossrefPubMedGoogle Scholar
• 35 Ramjiawan B, Czubryt M P, Gilchrist J SC, Pierce G N. Nuclear membrane cholesterol can modulate nuclear nucleoside triphosphatase activity.  J Cell Biochem. 1996;  63 442-452
  CrossrefPubMedGoogle Scholar
• 36 Scheuer K, Maras A, Gattaz W F, Cairns N, Förstl H, Müller W E. Cortical NMDA Receptor Properties and Membrane Fluidity are Altered in Alzheimer’s Disease.  Dementia. 1996;  7 210-214
  PubMedGoogle Scholar
• 37 Schroeder F, Frolov A A, Murphy E J, Atshaves B P, Jefferson J R, Pu L X, Wood W G, Foxworth W B, Kier A B. Recent advances in membrane cholesterol domain dynamics and intracellular cholesterol trafficking.  Proc Soc Exp Biol Med. 1996;  213 150-177
  PubMedGoogle Scholar
• 38 Simons K, Ikonen E. How cells handle cholesterol.  Science. 2000;  290 1721-1726
  CrossrefPubMedGoogle Scholar
• 39 Simons K, Toomre D. Lipid Rafts and Signal Transduction.  Nat Rev Mol Cell Biol. 2000;  1 31-39
  CrossrefPubMedGoogle Scholar
• 40 Simons M, Keller P, De Strooper B, Beyreuther K, Dotti C G, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.  Proc Natl Acad Sci USA. 1998;  95 6460-6464
  CrossrefPubMedGoogle Scholar
• 41 Singer S J, Nicolson G L. The fluid mosaic model of the structure of cell membranes.  Science. 1972;  175 720-731
  CrossrefPubMedGoogle Scholar
• 42 Svennerholm L, Gottfries C G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II).  J Neurochem. 1994;  62 1039-1047
  PubMedGoogle Scholar
• 43 Thiele C, Hannah M J, Fahrenholz F, Huttner W B. Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles.  Nat Cell Biol. 2000;  2 42-49
  CrossrefPubMedGoogle Scholar
• 44 Waschuk S, Elton E A, Darabie A A, Fraser P E, McLaurin J. Cellular membrane composition defines Aβ-lipid interactions.  J Biol Chem. 2001;  276 33 561-33 568
  PubMedGoogle Scholar
• 45 Wolozin B. Cholesterol and Alzheimer's disease.  Biochem Soc Trans. 2002;  30 525-529
  PubMedGoogle Scholar
• 46 Wolozin B, Kellman W, Ruosseau P, Celesia G G, Siegel G. Decreased prevalence of alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.  Arch Neurol. 2000;  57 1439-1443
  CrossrefPubMedGoogle Scholar
• 47 Wood W G, Eckert G P, Igbavboa U, Müller W E. Amyloid beta-protein interactions with membranes and cholesterol: causes and casualties of Alzheimer’s disease.  Biochim Biophys Acta. 2003;  1610 281-290
  PubMedGoogle Scholar
• 48 Wood W G, Schroeder F, Avdulov N A, Chochina S V, Igbavboa U. Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease.  Lipids. 1999;  34 225-234
  PubMedGoogle Scholar
• 49 Wood W G, Schroeder F, Igbavboa U, Avdulov N A, Chochina S V. Brain membrane cholesterol domains, aging and amyloid beta-peptides.  Neurobiol Aging. 2002;  23 685
  CrossrefPubMedGoogle Scholar
• 50 Yamaguchi H, Maat-Schieman M L, van Duinen S G, Prins F A, Neeskens P, Natte R, Roos R A. Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects.  J Neuropathol Exp Neurol. 2000;  59 723-732
  PubMedGoogle Scholar
• 51 Yankner B A, Duffy L K, Kirschner D A. Neurotrophic and neurotoxic effects of amyloid - beta protein: Reversal by tachykinin neuropeptides.  Science. 1990;  250 279-282
  PubMedGoogle Scholar
• 52 Yip C M, Darabie A A, McLaurin J. Abeta 1 - 42-Peptide assembly on lipid bilayers.  J Mol Biol. 2002;  318 97-107
  CrossrefPubMedGoogle Scholar
• 53 Zhou Y, Richardson J S. Cholesterol protects PC12 cells from beta-amyloid induced calcium disordering and cytotoxicity.  Neuroreport. 1996;  7 2487-2490
  PubMedGoogle Scholar

Dr. Gunter P. Eckert

Department of Pharmacology

Biocenter Niederursel

Phone: +49 (69) 79 82 93 78

Fax: +49 (69) 79 82 93 74

Email: G.P.Eckert@em.uni-frankfurt.de